Page 25 - Anjali Singh

GFL subsidiary GFCL EV raises Rs 1,000 cr to drive EV, ESS growth

The company's stock fell 6.94 per cent to Rs 4,386.85 per share on Wednesday on the BSE

Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%

The company, which operates 280 labs across India and is on track to open 15-20 new labs this year as part of its expansion efforts, is also exploring acquisitions in southern India

Hyundai Motor India drops 7% in market debut after country's biggest IPO

HMIL's IPO had seen strong response from sovereign wealth funds and domestic mutual funds, but retail and wealthy investors sidestepped the issue amid a selloff in auto stocks and overall markets

Hyundai Motor India confirms plans to launch hybrid vehicles soon

Also plans to expand EV portfolio and production capacity

Tata Motors receives order for 1000 diesel bus chassis from UPSRTC

This contract follows a previous order from UPSRTC for 1,350 bus chassis, which are currently operational across Uttar Pradesh

Luxe automakers on top gear to woo buyers in upscale lounge ambience

They are updating dealership networks to offer customers a more luxurious lounge

CEAT Q2FY25 results: Profit skids 41.4% to Rs 121.8 cr, revenue up 8.2%

CEAT took selective price increases during the quarter that offset part of the cost impact caused by higher rubber prices. The company remains optimistic for Q3

Bharat Forge to acquire axle maker AAM India for Rs 544.5 crore

Kalyani emphasised that this move aligns with Bharat Forge's broader strategy to diversify its offerings in vehicle components and enter a new product segment

Bajaj Auto Q2 results: Profit dips 31% to Rs 1,385 cr, revenue at Rs 13k cr

The domestic business achieved record-high revenue growth in double digits for the tenth consecutive quarter, driven by growth across motorcycles, commercial vehicles, and electric scooters

Festival fillip: Car dealerships see four-fold increase in footfall

Dealer sources claimed that even enquiries and bookings are up by 3-4 times when compared to the last 2-3 months

BMW India targets to double electric vehicle penetration by next year

BMW Group India has achieved its best-ever year-to-date car sales, with a 10 per cent growth in the first nine months of calendar year 2024

LML sues Bajaj Auto over unauthorised use of 'Freedom' trademark

According to the company, Bajaj's use of 'Freedom' infringes on its trademark rights, which is diluting its established reputation and the goodwill cultivated over decades

Two-wheeler sales witness surge ahead of festival season in India

Major players record 9-26% increase on strong domestic demand

NABH sets digital healthcare standards, 100 hospitals certified so far

A total of 300 hospitals had applied for the digital certification, which was introduced by NABH in 2023

Indian pharma companies set to see 9-11% growth in FY25, says Icra

The domestic market is expected to see a positive turnaround, with ICRA projecting revenue growth of 7-9 per cent for its sample set of companies in FY25

From EMIs to discounts, luxury car companies switch to festive gear

According to industry analysts, luxury car sales have remained steady, with a slight uptick in vehicle values driving overall revenue growth

SeQuent Scientific and Viyash Lifesciences announce strategic merger

The combined entity will have a stronger financial profile, enhanced R&D capabilities, and a streamlined supply chain, allowing it to serve global pharmaceutical clients more effectively

Results from Biocon Biologics supports interchangeability of psoriasis cure

Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and its biosimilar, adalimumab-fkjp

Price hikes improve margins for diagnostic labs amid online competition

Diagnostic companies like Metropolis Healthcare and Dr Lal PathLabs have implemented price hikes to cope with inflationary pressures

Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings

The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit profiles, even as pharma cos pursue acquisitions in niche therapeutic areas